Latest Avastin Stories
WALTHAM, Mass., Oct.
By ; wire Shares of South San Francisco-based Genentech dropped nearly 8 percent after the company announced with OSI Pharmaceuticals that a combination of two cancer drugs, Avastin with Tarceva, missed its primary goal in a clinical trial, failing to improve survival for patients with late-stage lung cancer.
Blockbuster cancer drug Avastin has suffered a setback, failing to improve overall survival when added to Tarceva in a Phase III trial for second-line advanced non-small cell lung cancer.
Genentech and OSI Pharmaceuticals have announced that a randomized Phase III study evaluating Avastin in combination with Tarceva in patients with advanced non-small cell lung cancer whose disease had progressed following platinum-based chemotherapy did not meet its primary endpoint of improving overall survival compared to Tarceva in combination with placebo.
Genentech, Inc. (NYSE:DNA) and OSI Pharmaceuticals, Inc.
By DOMINIC JEFF Herald Reporter A plymouth woman fighting to get a life-extending drug on the NHS has launched a petition for people to support her appeal. Stephanie Chouette, aged 34, has breast cancer which has spread to her vertebrae and liver, and has only a few months to live.
SCOTTSDALE, Ariz., Sept. 29 /PRNewswire/ -- NeoVista, Inc.
Roche has announced that the final analysis of the Avastin in lung study in patients with advanced lung cancer has shown that not only did the drug significantly slow down the disease progression, it also enabled some patients to survive for over one year, the longest survival ever reported in patients with this advanced disease.
WASHINGTON - What does a company do when there's anecdotal evidence that two of its drugs are equally effective in treating a leading cause of blindness in the elderly, one costing $60 per treatment and the other $2,000? In the case of Genentech Inc., nothing.
What does a company do when there's anecdotal evidence that two of its drugs are equally effective in treating a leading cause of blindness in the elderly, one costing patients $60 per treatment and the other $2,000? In the case of Genentech Inc., nothing.
- The act of sweetening by admixture of some saccharine substance.